RU2006142336A - PHARMACEUTICAL COMPOSITION BASED ON LADASTEN - Google Patents
PHARMACEUTICAL COMPOSITION BASED ON LADASTEN Download PDFInfo
- Publication number
- RU2006142336A RU2006142336A RU2006142336/15A RU2006142336A RU2006142336A RU 2006142336 A RU2006142336 A RU 2006142336A RU 2006142336/15 A RU2006142336/15 A RU 2006142336/15A RU 2006142336 A RU2006142336 A RU 2006142336A RU 2006142336 A RU2006142336 A RU 2006142336A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- ladasten
- salt
- stearic acid
- psychostimulating
- Prior art date
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
1. Фармацевтическая композиция с анксиолитическим, психостимулирующим и иммунотропным действием на основе ладастена, включающая в качестве действующего вещества терапевтически эффективное количество ладастена, а в качестве вспомогательного вещества - крахмал, стеариновую кислоту или ее соль при следующем соотношении компонентов, мас.%:2. Фармацевтическая композиция по п.1, отличающаяся тем, что в качестве крахмала она содержит крахмал картофельный.3. Фармацевтическая композиция по п.1, отличающаяся тем, что в качестве соли стеариновой кислоты используется преимущественно магниевая соль.4. Фармацевтическая композиция по п.1, отличающаяся тем, что она выполнена преимущественно в виде твердой лекарственной формы.5. Таблетки с анксиолитическим, психостимулирующим и иммунотропным действием, содержащие, мас.%:6. Таблетки по п.5 с содержанием действующего вещества от 0,05 до 0,2 г.7. Таблетки по пп.5 и 6 со средней массой от 0,1 до 0,4 г.8. Фармацевтическая композиция с анксиолитическим, психостимулирующим и иммунотропным действием на основе ладастена, включающая в качестве действующего вещества терапевтически эффективное количество ладастена, а в качестве вспомогательных веществ - лудипресс, стеариновую кислоту или ее соль при следующем соотношении компонентов, мас.%:9. Фармацевтическая композиция по п.8, отличающаяся тем, что в качестве соли стеариновой кислоты используется преимущественно магниевая соль.10. Фармацевтическая композиция по п.8, отличающаяся тем, что она выполнена преимущественно в виде твердой лекарственной формы.11. Таблетки с анксиолитическим, психостимулирующим и иммунотропным действием, содержащие, мас.1. A pharmaceutical composition with anxiolytic, psychostimulating and immunotropic effects on the basis of Ladasten, comprising as the active substance a therapeutically effective amount of Ladasten, and as an adjuvant, starch, stearic acid or its salt in the following ratio, wt.%: 2. The pharmaceutical composition according to claim 1, characterized in that it contains potato starch as starch. The pharmaceutical composition according to claim 1, characterized in that the magnesium salt is predominantly used as the stearic acid salt. The pharmaceutical composition according to claim 1, characterized in that it is made mainly in the form of a solid dosage form. Tablets with anxiolytic, psychostimulating and immunotropic effects, containing, wt.%: 6. Tablets according to claim 5 with an active substance content of from 0.05 to 0.2 g. 7. Tablets according to claims 5 and 6 with an average weight of 0.1 to 0.4 g. 8. A pharmaceutical composition with anxiolytic, psychostimulating and immunotropic effects on the basis of Ladasten, comprising as the active substance a therapeutically effective amount of Ladasten, and as excipients, ludipress, stearic acid or its salt in the following ratio, wt.%: 9. The pharmaceutical composition of claim 8, characterized in that the magnesium salt is preferably used as the stearic acid salt. The pharmaceutical composition of claim 8, characterized in that it is made mainly in the form of a solid dosage form. Tablets with anxiolytic, psychostimulating and immunotropic effects, containing, by weight.
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2006142336/15A RU2376986C2 (en) | 2006-11-30 | 2006-11-30 | Pharmaceutical composition based on ladasten |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2006142336/15A RU2376986C2 (en) | 2006-11-30 | 2006-11-30 | Pharmaceutical composition based on ladasten |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2006142336A true RU2006142336A (en) | 2008-06-20 |
RU2376986C2 RU2376986C2 (en) | 2009-12-27 |
Family
ID=41643188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006142336/15A RU2376986C2 (en) | 2006-11-30 | 2006-11-30 | Pharmaceutical composition based on ladasten |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2376986C2 (en) |
-
2006
- 2006-11-30 RU RU2006142336/15A patent/RU2376986C2/en active
Also Published As
Publication number | Publication date |
---|---|
RU2376986C2 (en) | 2009-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2007119641A (en) | COMPOSITION INCLUDING ACETAMINOPHEN, CAFFEINE AND OPTIONAL ASPIRINE IN A MIXTURE WITH AN ALKALINE AGENT FOR INCREASING ABSORPTION | |
RU2008115582A (en) | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PARKINSON'S DISEASE | |
RU2013126056A (en) | COMPOSITION FOR TREATMENT OF INVERVATION DISORDERS (OPTIONS) | |
RU2006142336A (en) | PHARMACEUTICAL COMPOSITION BASED ON LADASTEN | |
RU2009101126A (en) | PHARMACEUTICAL COMPOSITION WITH ANTIPSYCHOTIC ACTION | |
RU2008139377A (en) | SOLID DOSED MEDICINAL FOR TREATMENT OF DIABETES | |
RU2009114885A (en) | PHARMACEUTICAL COMPOSITION IN THE FORM OF A SOLID ORAL DRUG FORM FOR THE TREATMENT OF DISEASES OF THE GASTROINTESTINAL TRACT | |
RU2006116540A (en) | SOLID DOSED MEDICINAL FOR TREATMENT OF DIABETES | |
RU2004118448A (en) | PHARMACEUTICAL COMPOSITION WITH PROLONGED GLYCLAZIDE RELEASE | |
RU2008113043A (en) | PHARMACEUTICAL COMPOSITION WITH ANTI-MIRACLE ACTION | |
RU2008147739A (en) | COMBINED ANTI-TUBERCULOSIS PHARMACEUTICAL COMPOSITION | |
RU2007112544A (en) | PHARMACEUTICAL COMPOSITION HAVING ANTI-VESSEL AND PSYCHOTROPIC ACTION | |
RU2004123356A (en) | PHARMACEUTICAL COMPOSITION BASED ON AFOBAZOLE | |
RU2016146653A (en) | PHARMACEUTICAL COMPOSITION BASED ON CHLORBENZOYLAMINOADAMANTHANE, INCREASING PHYSICAL PERFORMANCE IN THE CONDITIONS OF HIGH AND LOW TEMPERATURES | |
RU2004123357A (en) | PHARMACEUTICAL COMPOSITION BASED ON NOOPEPT | |
RU2008149236A (en) | PHARMACEUTICAL COMPOSITION HAVING ANTI-INFLAMMATORY AND ANTIBACTERIAL ACTION (OPTIONS) | |
RU2010134123A (en) | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ALLERGIC DISEASES | |
RU2006120323A (en) | EXTRACT OF FICO AND MICRBIONATE Cetraria islandica (L.) Ach. DRY AND HIS TABLET FORM | |
RU2016146645A (en) | PHARMACEUTICAL COMPOSITION OF 1-HYDROXY-4-CYCLOHEXYLAMINOADAMANTANE HYDROCHLORIDE AND SODIUM OF 4-HYDROXYXOXYLIC ACID, IMPROVING MENTAL AND PHYSICAL PERFORMANCE | |
RU2006135449A (en) | PHARMACOLOGICAL COMPOSITION HAVING ANTIBACTERIAL AND FUNGICIDAL ACTION | |
RU2011104563A (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ARTERIAL HYPERTENSION AND CONSTANT HEART FAILURE AND METHOD FOR ITS PRODUCTION | |
RU2003104272A (en) | ANTIFUNGAL PHARMACEUTICAL COMPOSITION | |
RU2005136202A (en) | SOLID DOSMINE DOSAGE FORM | |
RU2008132922A (en) | METHOD FOR TREATING DAMAGES OF ORGANISM SYSTEMS DUE TO ACTIVATION OF THE PEROXIDATION PROCESS PROCESS AND THE LIQUID PHARMACEUTICAL COMPOSITION FOR ITS IMPLEMENTATION | |
RU2013157797A (en) | PHARMACEUTICAL COMPOSITION FOR TREATING SUGAR DIABETES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PD4A | Correction of name of patent owner | ||
PD4A | Correction of name of patent owner |